8-K - TuHURA Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

TuHURA Biosciences reported its 2025 financial results, highlighting increased R&D spending and net cash outflows, while providing updates on clinical trial progress and upcoming milestones across its immuno-oncology pipeline.

Key Takeaways

1Research and development expenses increased to $20.5 million in 2025 from $13.3 million in 2024, reflecting investment in clinical programs.

2Net cash outflows from operating activities were $27.7 million in 2025, up from $14.7 million in 2024, indicating higher operational spending.

3The company closed acquisition of Kineta for $10.5 million, gaining rights to VISTA inhibiting antibody TBS-2025.

4TuHURA raised $21.2 million in registered direct offerings and private placements to fund operations and development.

5The Phase 3 trial for IFx-2.0 in Merkel Cell Carcinoma continues enrollment with completion anticipated in mid-2027.

6Upcoming milestones include FDA meetings for TBS-2025 in June 2026 and anticipated orphan drug designation for IFx-2.0 in 1H 2026.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its finan

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 99.1 Press Release, dated April 1, 2026 104 Cover Page Interactive Data File (embedded wit

Exhibits Only

Source Document

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Research and Development Expenses	$20.50	GAAP	$13.30
General and Administrative Expenses	$7.60	GAAP	$3.90

Transaction Details

Acquisition / Disposition

Target: Kineta (gaining rights to TBS-2025)
Consideration: $10.5 million
Structure: acquisition

•Closed acquisition of Kineta

Exhibits (2)

8-K

99.1

EX-99.1